Biofrontera Inc (BFRI)

$1.01

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $1.00
    $1.05
    $1.01
    downward going graph

    0.91%

    Downside

    Day's Volatility :4.69%

    Upside

    3.81%

    downward going graph
  • $0.61
    $12.99
    $1.01
    downward going graph

    39.6%

    Downside

    52 Weeks Volatility :95.3%

    Upside

    92.22%

    downward going graph

Returns

PeriodBiofrontera IncIndex (Russel 2000)
3 Months
-32.44%
0.0%
6 Months
-39.16%
0.0%
1 Year
-92.07%
0.0%
3 Years
-98.85%
-19.9%

Highlights

Market Capitalization
5.1M
Book Value
- $1.06
Earnings Per Share (EPS)
-10.3
Wall Street Target Price
16.0
Profit Margin
-69.44%
Operating Margin TTM
-69.1%
Return On Assets TTM
-41.79%
Return On Equity TTM
-309.83%
Revenue TTM
33.3M
Revenue Per Share TTM
15.7
Quarterly Revenue Growth YOY
-9.4%
Gross Profit TTM
13.5M
EBITDA
-21.7M
Diluted Eps TTM
-10.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.74
EPS Estimate Next Year
-0.25
EPS Estimate Current Quarter
-1.17
EPS Estimate Next Quarter
-1.12

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Biofrontera Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1484.16%

Current $1.01
Target $16.00

Company Financials

FY19Y/Y Change
Revenue
26.2M
-
Net Income
-11.0M
-
Net Profit Margin
-41.95%
-
FY20Y/Y Change
Revenue
18.8M
↓ 28.01%
Net Income
-11.0M
↑ 0.05%
Net Profit Margin
-58.29%
↓ 16.34%
FY21Y/Y Change
Revenue
24.1M
↑ 27.86%
Net Income
-37.7M
↑ 243.25%
Net Profit Margin
-156.49%
↓ 98.2%
FY22Y/Y Change
Revenue
28.7M
↑ 18.98%
Net Income
-640.0K
↓ 98.3%
Net Profit Margin
-2.23%
↑ 154.26%
FY23Y/Y Change
Revenue
34.1M
↑ 18.82%
Net Income
-20.1M
↑ 3045.47%
Net Profit Margin
-59.09%
↓ 56.86%
Q4 FY22Q/Q Change
Revenue
10.1M
↑ 134.71%
Net Income
-2.8M
↑ 8.53%
Net Profit Margin
-27.45%
↑ 31.92%
Q1 FY23Q/Q Change
Revenue
8.7M
↓ 13.91%
Net Income
-7.5M
↑ 168.51%
Net Profit Margin
-85.63%
↓ 58.18%
Q2 FY23Q/Q Change
Revenue
5.8M
↓ 33.04%
Net Income
-9.8M
↑ 31.55%
Net Profit Margin
-168.21%
↓ 82.58%
Q3 FY23Q/Q Change
Revenue
8.9M
↑ 51.83%
Net Income
-6.3M
↓ 35.53%
Net Profit Margin
-71.43%
↑ 96.78%
Q4 FY23Q/Q Change
Revenue
10.6M
↑ 19.34%
Net Income
3.5M
↓ 155.6%
Net Profit Margin
33.28%
↑ 104.71%
Q1 FY24Q/Q Change
Revenue
7.9M
↓ 25.43%
Net Income
-10.4M
↓ 396.0%
Net Profit Margin
-132.1%
↓ 165.38%
FY19Y/Y Change
Total Assets
28.8M
-
Total Liabilities
58.9M
-
FY20Y/Y Change
Total Assets
24.1M
↓ 16.05%
Total Liabilities
18.3M
↓ 68.93%
FY21Y/Y Change
Total Assets
53.2M
↑ 120.48%
Total Liabilities
41.9M
↑ 128.73%
FY22Y/Y Change
Total Assets
50.9M
↓ 4.39%
Total Liabilities
27.0M
↓ 35.52%
FY23Y/Y Change
Total Assets
27.9M
↓ 45.11%
Total Liabilities
23.1M
↓ 14.32%
Q4 FY22Q/Q Change
Total Assets
50.9M
↓ 7.58%
Total Liabilities
27.0M
↓ 16.82%
Q1 FY23Q/Q Change
Total Assets
42.0M
↓ 17.53%
Total Liabilities
25.2M
↓ 6.63%
Q2 FY23Q/Q Change
Total Assets
36.9M
↓ 12.06%
Total Liabilities
29.7M
↑ 17.92%
Q3 FY23Q/Q Change
Total Assets
34.1M
↓ 7.59%
Total Liabilities
33.1M
↑ 11.21%
Q4 FY23Q/Q Change
Total Assets
27.9M
↓ 18.1%
Total Liabilities
23.1M
↓ 30.02%
Q1 FY24Q/Q Change
Total Assets
24.6M
↓ 12.02%
Total Liabilities
30.0M
↑ 29.61%
FY19Y/Y Change
Operating Cash Flow
-37.7M
-
Investing Cash Flow
25.4M
-
Financing Cash Flow
16.4M
-
FY20Y/Y Change
Operating Cash Flow
-12.4M
↓ 67.17%
Investing Cash Flow
-11.0K
↓ 100.04%
Financing Cash Flow
13.2M
↓ 19.55%
FY21Y/Y Change
Operating Cash Flow
-26.7M
↑ 115.98%
Investing Cash Flow
-11.0K
↑ 0.0%
Financing Cash Flow
43.2M
↑ 227.35%
FY22Y/Y Change
Operating Cash Flow
-16.2M
↓ 39.36%
Investing Cash Flow
-5.2M
↑ 46772.73%
Financing Cash Flow
14.0M
↓ 67.54%
Q4 FY22Q/Q Change
Operating Cash Flow
-8.3M
↑ 39.22%
Investing Cash Flow
-2.1M
↓ 31.25%
Financing Cash Flow
-9.4M
↓ 302.83%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.7M
↓ 55.4%
Investing Cash Flow
178.0K
↓ 108.53%
Financing Cash Flow
1.1M
↓ 111.78%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.3M
↑ 180.18%
Investing Cash Flow
178.0K
↑ 0.0%
Financing Cash Flow
1.1M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Biofrontera Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biofrontera Inc
Biofrontera Inc
12.15%
-39.16%
-92.07%
-98.85%
-98.85%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.73%
3.47%
45.25%
47.46%
69.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
3.24%
7.6%
2.41%
20.38%
20.38%
Zoetis Inc.
Zoetis Inc.
5.19%
-3.9%
-2.6%
-11.21%
55.91%
Viatris Inc.
Viatris Inc.
11.46%
-0.85%
9.89%
-16.16%
-28.58%
Catalent, Inc.
Catalent, Inc.
3.12%
18.35%
21.46%
-49.91%
6.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biofrontera Inc
Biofrontera Inc
NA
NA
NA
-2.74
-3.1
-0.42
NA
-1.06
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.48
39.48
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.7
29.7
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.34
34.34
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biofrontera Inc
Biofrontera Inc
Buy
$5.1M
-98.85%
NA
-69.44%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
69.5%
39.48
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
20.38%
29.7
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.5B
55.91%
34.34
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.9B
-28.58%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
6.12%
211.02
-28.44%

Insights on Biofrontera Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 10.59M → 7.90M (in $), with an average decrease of 25.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 3.52M → -10.43M (in $), with an average decrease of 396.0% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 47.1% return, outperforming this stock by 138.7%

Institutional Holdings

  • Rosalind Advisors, Inc.

    9.91%
  • AIGH Capital Management, LLC

    9.85%
  • Scotia Capital Inc

    0.79%
  • XTX Topco Ltd

    0.24%
  • HRT FINANCIAL LLC

    0.21%
  • Renaissance Technologies Corp

    0.20%

Company Information

biofrontera pharma gmbh is a pharmaceuticals company based out of 104 waldhofer straße, heidelberg, bw, germany.

Organization
Biofrontera Inc
Employees
83
CEO
Dr. Hermann Luebbert Ph.D.
Industry
Miscellaneous

FAQs